Tuberculosis is the leading cause of death due to an infectious disease despite effective medications to treat and prevent this infection. The only available TB vaccine, BCG, has variable effectiveness but is most effective against miliary and meningeal TB, two severe forms of extrapulmonary TB. BCG also appears to be more effective in young children than it is in adults. Interestingly, extrapulmonary TB in general, and miliary and meningeal TB in particular, are more common in young children than in adults. The factors which predispose HIV-seronegative children and adults to extrapulmonary TB are unknown, as are the factors which underlie the age-related differences in the clinical manifestations of TB. Interferon-gamma is critical in the host immune response to mycobacterial infections. Defects in interferon-gamma production and genetic abnormalities that result in defects in the interferon-gamma receptor, have been identified in HIV- seronegative children with disseminated nontuberculosis mycobacterial infections. Interferon-gamma is also critical in the host immune response to M. tuberculosis infection. We hypothesize that abnormalities in the interferon-gamma cytokine response pathway contribute to the development of extrapulmonary or disseminated TB. We propose to investigate the risk factors for extrapulmonary TB through four case-control studies. First, we will compare cytokine responses to mitogen stimulation in HIV- seronegative adults with extrapulmonary TB compared to the cytokine response in PPD+ adults without active TB. Second, we will compare cytokine responses in children less than 5 years old with miliary/meningeal TB to PPD+ children less than 5 years old without active TB.
The third aim of this proposal is to assess for the prevalence of genetic abnormalities specific to the interferon-gamma cytokine response pathway among persons with extrapulmonary TB and controls in the same two populations. New insights into the predisposition to disseminated or extrapulmonary TB will increase our understanding of the pathogenesis of M. tubercuolosis infection, and help identify persons at risk for these severe forms of TB. These investigations will also help identify persons who would benefit most from TB vaccination. The insights gained may also lead to an improved understanding of the mechanisms through which BCG protects against TB, and identify ways in which to develop a more effective TB vaccine.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Mentored Patient-Oriented Research Career Development Award (K23)
Project #
5K23AI001654-04
Application #
6653152
Study Section
Microbiology and Infectious Diseases B Subcommittee (MID)
Program Officer
Sizemore, Christine F
Project Start
2000-09-01
Project End
2003-06-30
Budget Start
2003-06-01
Budget End
2003-06-30
Support Year
4
Fiscal Year
2003
Total Cost
$9,909
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Motsinger-Reif, Alison A; Antas, Paulo R Z; Oki, Noffisat O et al. (2010) Polymorphisms in IL-1beta, vitamin D receptor Fok1, and Toll-like receptor 2 are associated with extrapulmonary tuberculosis. BMC Med Genet 11:37
Pepper, T; Joseph, P; Mwenya, C et al. (2008) Normal chest radiography in pulmonary tuberculosis: implications for obtaining respiratory specimen cultures. Int J Tuberc Lung Dis 12:397-403
Sterling, Timothy R; Martire, Terezinha; de Almeida, Alexandre Silva et al. (2007) Immune function in young children with previous pulmonary or miliary/meningeal tuberculosis and impact of BCG vaccination. Pediatrics 120:e912-21
Antas, Paulo R Z; Ding, Li; Hackman, Judith et al. (2006) Decreased CD4+ lymphocytes and innate immune responses in adults with previous extrapulmonary tuberculosis. J Allergy Clin Immunol 117:916-23
Ritchie, Marylyn D; Haas, David W; Motsinger, Alison A et al. (2006) Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin Infect Dis 43:779-82
Dooley, Kelly E; Sterling, Timothy R (2005) Treatment of latent tuberculosis infection: challenges and prospects. Clin Chest Med 26:313-26, vii
Sterling, Timothy R; Pisell-Noland, Tracy; Perez, John L et al. (2005) Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals. J Infect Dis 191:881-5
Hulgan, Todd; Raffanti, Stephen; Kheshti, Asghar et al. (2005) CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3. J Infect Dis 192:950-7
Sterling, T R (2004) The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls. Int J Tuberc Lung Dis 8:1396-400
Ginsburg, Amy Sarah; Hooper, Nancy; Parrish, Nikki et al. (2003) Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 37:1448-52

Showing the most recent 10 out of 23 publications